Drug Trial Radar · NCT07817706
Development of a Noninvasive Metric to Measure Small Bowel Sensation - The Small Intestine Stress Test
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Jun 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this research is to identify the concentration of mannitol solution (a type of sugar alcohol) that will generate a range of symptoms in individuals without Disorders of Gut Brain Interaction (DGBI) to establish the normative range of responses to small bowel (SB) distension.
Conditions
- Disorders of Gut Brain Interaction
Interventions
Mannitol Solution 76 mOsm/LDrug
Participants will ingest 500 mL of mannitol solution at 76 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.
Mannitol Solution 189 mOsm/LDrug
Participants will ingest 500 mL of mannitol solution at 189 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.
Mannitol Solution 325 mOsm/LDrug
Participants will ingest 500 mL of mannitol solution at 325 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.
ScintigraphyDiagnostic test
Scintigraphy will be used to track gastric emptying, small bowel transit, and colonic filling of the radiolabeled mannitol solution during each testing visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Gastrointestinal Symptom Severity During Small Bowel Transit Following 76 mOsm/L Mannitol Solution IngestionTime frame: At baseline and at 15-minute intervals beginning 30 minutes after ingestion through 180 minutes post-ingestion.
- Peak Gastrointestinal Symptom Severity During Small Bowel Transit Following 189 mOsm/L Mannitol Solution IngestionTime frame: At baseline and at 15-minute intervals beginning 30 minutes after ingestion through 180 minutes post-ingestion.
- Peak Gastrointestinal Symptom Severity During Small Bowel Transit Following 325 mOsm/L Mannitol Solution IngestionTime frame: At baseline and at 15-minute intervals beginning 30 minutes after ingestion through 180 minutes post-ingestion.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.